Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, DENTSPLY Sirona Inc’s stock clocked out at $12.35, up 1.81% from its previous closing price of $12.13. In other words, the price has increased by $1.81 from its previous closing price. On the day, 3.53 million shares were traded. XRAY stock price reached its highest trading level at $12.64 during the session, while it also had its lowest trading level at $12.16.
Ratios:
To gain a deeper understanding of XRAY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.79 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 30.81. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 1.47. In the meantime, Its Debt-to-Equity ratio is 1.68 whereas as Long-Term Debt/Eq ratio is at 1.42.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Underweight rating and assigned the stock a target price of $12.
Morgan Stanley Downgraded its Overweight to Equal-Weight on April 15, 2025, while the target price for the stock was maintained at $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 08 ’25 when LUCIER GREGORY T bought 82,200 shares for $11.10 per share.
LUCIER GREGORY T sold 82,200 shares of XRAY for $915,708 on Dec 08 ’25. The Director now owns 0 shares after completing the transaction at $11.14 per share. On Nov 24 ’25, another insider, VARON LESLIE F, who serves as the Director of the company, bought 9,337 shares for $10.71 each. As a result, the insider paid 99,999 and bolstered with 57,343 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XRAY now has a Market Capitalization of 2464466944 and an Enterprise Value of 4595466752. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 8.85. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.68 while its Price-to-Book (P/B) ratio in mrq is 1.67. Its current Enterprise Value per Revenue stands at 1.268 whereas that against EBITDA is 7.521.
Stock Price History:
The Beta on a monthly basis for XRAY is 1.02, which has changed by -0.34219086 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, XRAY has reached a high of $20.59, while it has fallen to a 52-week low of $9.85. The 50-Day Moving Average of the stock is 8.58%, while the 200-Day Moving Average is calculated to be -9.59%.
Shares Statistics:
It appears that XRAY traded 3.74M shares on average per day over the past three months and 4208540 shares per day over the past ten days. A total of 199.50M shares are outstanding, with a floating share count of 198.26M. Insiders hold about 0.65% of the company’s shares, while institutions hold 105.19% stake in the company. Shares short for XRAY as of 1767139200 were 14976914 with a Short Ratio of 4.00, compared to 1764288000 on 14200459. Therefore, it implies a Short% of Shares Outstanding of 14976914 and a Short% of Float of 8.37.
Dividends & Splits
With its trailing 12-month dividend rate of 0.64, XRAY has a forward annual dividend rate of 0.64. Against a Trailing Annual Dividend Yield of 0.052761745. The stock’s 5-year Average Dividend Yield is 2.05.
Earnings Estimates
The market rating of DENTSPLY Sirona Inc (XRAY) is currently shaped by the ongoing analysis conducted by 16.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.39, with high estimates of $0.55 and low estimates of $0.28.
Analysts are recommending an EPS of between $1.83 and $1.58 for the fiscal current year, implying an average EPS of $1.62. EPS for the following year is $1.56, with 16.0 analysts recommending between $1.79 and $1.15.
Revenue Estimates
In. The current quarter, 14 analysts expect revenue to total $926.74M. It ranges from a high estimate of $964M to a low estimate of $892M. As of. The current estimate, DENTSPLY Sirona Inc’s year-ago sales were $905MFor the next quarter, 14 analysts are estimating revenue of $899.93M. There is a high estimate of $926.15M for the next quarter, whereas the lowest estimate is $887M.
A total of 17 analysts have provided revenue estimates for XRAY’s current fiscal year. The highest revenue estimate was $3.68B, while the lowest revenue estimate was $3.61B, resulting in an average revenue estimate of $3.65B. In the same quarter a year ago, actual revenue was $3.79BBased on 16 analysts’ estimates, the company’s revenue will be $3.68B in the next fiscal year. The high estimate is $3.77B and the low estimate is $3.55B.
